1203O FOLFOX plus nivolumab and ipilimumab versus FOLFOX induction followed by nivolumab and ipilimumab in patients with previously untreated advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction: Results from the randomized phase II Moonlight trial of the AIO

Authors :: S. Lorenzen
P.C. Thuss-Patience
G. Folprecht
J. Riera Knorrenschild
V. Heinemann
E. Goekkurt
T.N. Dechow
T.J. Ettrich
K.B. Luley
J-C. Moulin
U. Lindig
S. Angermeier
O. Waidmann
D. Pink
C. Bolling
S. Junge
C. Pauligk
T. Gaiser
T.O. Götze
S-E. Al-Batran
Source :: Annals of Oncology. 33:S1099
Publication Year :: 2022
Publisher :: Elsevier BV, 2022.

Tools